severe primary IGF-1 deficiency
Endocrinology · 2021–2021
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mecasermin Long-term treatment of growth failure in children and adolescents from 2 to 18 years with severe primary insulin-like growth factor 1 deficiency (SPIGFD). | Nov 2021 | Not recommended | input received GH Insensitivity Syndrome Collaborative Group · IGF Society |
Who spoke
GH Insensitivity Syndrome Collaborative Group · IGF Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.